Hepatodeject 500ml
DESCRIPTION
Hepatojekt (Hepatojekt) - injection solution for the treatment of liver diseases of various etiologies in animals. In appearance, the drug is a colorless transparent solution.
COMPOSITION
Hepatoject as active ingredients in 1 ml contains: L-ornithine - 15 mg, L-citrulline - 10 mg, L-arginine - 40 mg, as well as auxiliary substances: betaine - 15 mg, sorbitol - 200 mg, lidocaine hydrochloride - 1 mg, methylparaben - 0.5 mg, propylparaben - 0.2 mg and water for injection - up to 1 ml.
PHARMACOLOGICAL PROPERTIES
Hepatoject belongs to the group of combined hepatoprotective drugs.
The hepatoprotective effect of the drug is due to the properties of its constituent components.
L-ornithine, participating in the ornithine cycle of Krebs urea formation (the formation of urea from ammonia), reduces the level of ammonia in the body, increased in liver diseases, promotes the synthesis of insulin and growth hormone, activates protein metabolism.
L-citrulline is an amino acid that participates in the urea cycle and promotes the formation and elimination of urea from the body.
L-arginine (amino-guanidyl-valeric acid) stimulates cell metabolism, promotes the neutralization and elimination of ammonia, regulates blood sugar and reduces lactic acidosis caused by muscle load, activates the system of nitrogen-containing enzymes that synthesize the nitroso group (NO), providing the necessary tonicity of the arteries ...
Betaine (trimethylglycine) has a choleretic and lipotropic effect, activates metabolic methylation in the liver and the synthesis of phospholipids of cell membranes. Acting as an alternative donor of methyl groups in the conversion of methionine from homocysteine, it can replace defects in methylation reactions caused by dysfunction of the folate cycle and a lack of vitamin B12.
Sorbitol has a detoxification and choleretic effect, provides replenishment of the BCC.
The drug is rapidly absorbed from the injection site, passes the histohematogenous barriers and is distributed to all organs and tissues. Partially utilized in metabolic processes, the remainder is excreted by the kidneys (mainly).
According to the degree of impact on the body, hepatodeject belongs to low-hazard substances (hazard class 4 according to GOST 12.1.007-76), in therapeutic doses it does not have embryotoxic, teratogenic, carcinogenic and sensitizing effects.
DOSAGE AND APPLICATION
Hepatoject is prescribed to animals independently or as part of complex therapy for acute and chronic liver diseases of various etiologies, in order to normalize the function and regeneration of liver cells after endo- and exotoxicosis, somatic and infectious diseases, and also to reduce the hepatotoxic effect of drugs.
Hepatoject is administered to the animal subcutaneously, deeply intramuscularly or slowly intravenously in the doses indicated in the table; the course of administration is 1-2 times a day for 5-7 days:
Kind of animal Single dose of Hepatoject per animal
Dogs 2-5 ml
Cats 2-5 ml
Horses 50-100 ml
Cattle (adult) 50-100 ml
Pigs, sheep (adults) Pigs, sheep (adults) 10-15 ml
Piglets, lambs 3-5 ml
Foals, calves 1 ml per 5-10 kg of animal weight
Note: foals - horses up to 1 year old, lambs - sheep up to 4 months of age, calves and pigs - animals up to 6 months of age.
The course of the drug can be extended up to 2 weeks at the discretion of the attending veterinarian.
SPECIAL INSTRUCTIONS
The peculiarities of the action of the Hepatoject at its first application or cancellation have not been identified.
Skipping the next dose of the drug should be avoided, as this can lead to a decrease in its therapeutic efficacy. If one dose is missed, the use of the drug is resumed in the same dosage and according to the same scheme.
There is no information about the incompatibility of Hepatoject with other drugs and feed additives.
Slaughter of animals for meat is allowed no earlier than 24 hours after the last application of Hepatoject.
The meat of animals that were forcedly killed before the expiration of the specified period can be used as feed for fur animals.
Milk obtained from animals during the treatment period and within 24 hours (2 milkings) after the last injection of the drug must not be used for food purposes. Such milk after heat treatment can be used in animal feed.
CONTRAINDICATIONS
Contraindication to use is the increased individual sensitivity of the animal to the components of the drug (including a history).
SIDE EFFECTS
As a rule, there are no side effects and complications when using Hepatodeject in accordance with this instruction. In case of increased individual sensitivity of the animal to the components of the drug and the appearance of allergic reactions, its use is stopped and, if necessary, antihistamines and symptomatic therapy are prescribed to the animal.
SHELF LIFE AND STORAGE
Store the drug in the manufacturer's closed packaging, in a dry, dark place, separate from food and feed, at a temperature of 5 В° C to 25 В° C.
The shelf life of the medicinal product, subject to storage conditions in a sealed package, is 2 years from the date of production, after opening the bottle, subject to aseptic conditions - 21 days.
PACKAGING
The preparation is produced in 500 ml vials made of dark glass, sealed with a rubber stopper with an aluminum cap.
Specifications
KolVUP
6
Manufacturer
APICENNA
Teaser
drug for the treatment of liver diseases of various etiologies in animals